Sign Up Today and Learn More About VivaVision Biotech Stock
Invest in or calculate the value of your shares in VivaVision Biotech or other pre-IPO companies through EquityZen's platform.
VivaVision Biotech Stock (VIVB)
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases.
About VivaVision Biotech Stock
Founded
2016
Industries
Science and Engineering, Biotechnology
VivaVision Biotech Press Mentions
Stay in the know about the latest news on VivaVision Biotech
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
en • Jun 10, 2025
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
prnewswire • Jun 09, 2025
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
en • Apr 24, 2025
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
thailand-business-news • Apr 24, 2025
Global Post-Operative Cataract Surgery Inflammation Treatment Market Outlook 2025-2034: Growth Drivers, And Trends
einpresswire • Mar 27, 2025
VivaVision Biotech Management
Leadership team at VivaVision Biotech
CEO, Chairman, President & Founder
Wang Shen
Join now and verify your accreditation status to gain access to:
- VivaVision Biotech Current Valuation
- VivaVision Biotech Stock Price
- VivaVision Biotech Management
- Available deals in VivaVision Biotech and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- VivaVision Biotech Cap Table and Funding History by Share Class and Liquidity Preferences
- VivaVision Biotech Revenue and Financials
- VivaVision Biotech Highlights
- VivaVision Biotech Business Model
- VivaVision Biotech Risk Factors
- VivaVision Biotech Research Report from SACRA Research
Trading VivaVision Biotech Stock
How to invest in VivaVision Biotech stock?
Accredited investors can buy pre-IPO stock in companies like VivaVision Biotech through EquityZen funds. These investments are made available by existing VivaVision Biotech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell VivaVision Biotech stock?
Shareholders can sell their VivaVision Biotech stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
